Cantor Fitzgerald Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains a Neutral rating on Sarepta Therapeutics and raises the price target from $40 to $80.
November 02, 2023 | 1:54 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has maintained a Neutral rating on Sarepta Therapeutics but raised the price target from $40 to $80.
The news is directly about Sarepta Therapeutics. The maintained Neutral rating suggests that the analyst does not expect significant price movement in the short term. However, the raised price target could indicate a positive long-term outlook, which might attract investors.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100